5-FU local injection for the treatment of advanced gastric cancer
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0008395
- Lead Sponsor
- Kangbuk Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
Patients aged 18 years or older with histologically confirmed adenocarcinoma and diagnosed with advanced gastric cancer that is not amenable to radical resection at the time of diagnosis who meet the following conditions are eligible.
Patients who have failed standard treatment or for whom standard treatment is not feasible,
Patients with measurable lesions in the stomach on endoscopy,
Patients with a predicted survival time of 3 months or more.
?Patients with a history of cancer other than gastric cancer
?Patients who do not consent to this treatment
?Nursing mothers other than pregnant women or women of childbearing potential who are planning to become pregnant
?Patients receiving Tegapur-Gimeracil-Oterasil potassium combination and patients who have stopped taking it within 7 days.
?Patients receiving sorbudine
?Patients with a history of severe hypersensitivity to 5-FU
?Patients with bone marrow depression after treatment with other antineoplastic agents, radiation therapy, or extreme frailty
?Patients with non-malignant tumor disease
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate (ORR; objective response rate): Percentage of patients with an objective response, such as a reduction in tumor size, relative to the total number of patients.
- Secondary Outcome Measures
Name Time Method Changes in tumor size and area on endoscopy